Jennewein Biotechnologie develops new fermentation technology for human milk oligosaccharides and expands its product portfolio
Photo by Rainier Ridao on Unsplash
Jennewein Biotechnologie has recently developed processes for the complete biosynthesis of complex HMOs from simple carbon sources rather than lactose. “The introduction of total biosynthesis concepts makes the fermentation process more robust and also more cost effective,” states Dr. Stefan Jennewein (CEO). “The last point is particularly relevant because even the most advanced infant formulae contain lower concentrations of HMOs than natural human milk.” Glyn Brookman (Director of Sales) takes up the story: “In order to replace unnecessary HMO surrogates, like Galactooligosaccharides (GOS) and Fructooligosaccharides (FOS), in infant formulae, the cost of HMOs must be addressed.”
Dr. Benedikt Engels (Chief Operation Officer) continues: “The new total biosynthesis process will initially replace our current large-scale fermentation process for the production of 2′-fucosyllactose, and will also be used to produce lacto-N-neotetraose.” Dr. Stefan Jennewein sums up the promise of the new technology: “The introduction of our total biosynthesis concept for HMOs is a big leap forward in our mission to bring the significant health benefits of HMOs into every infant formula product for the benefit of all babies.”
Topics
Organizations
Other news from the department research and development
Get the food & beverage industry in your inbox
From now on, don't miss a thing: Our newsletter for the food & beverage sector brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.